PBR Nachrichten

 

The collaboration aims to conduct a full technical and operational assessment of Cellares' automated manufacturing and testing platforms. This is in preparation for the anticipated demand surrounding TSC-101 The post Cellares and TScan to assess automated manufacturing of TSC-101 therapy appeared first on Pharmaceutical Business review....

The collaboration combines CytomX's Probody technology with Regeneron's Veloci‑Bi bispecific platform to target hard‑to‑treat tumour types. Established in 2022, the partnership combines CytomX's biologic masking technology with Regeneron's The post Regeneron and CytomX extend cancer therapy partnership to $4bn deal appeared first on Pharmaceutical Business review....

This marks the second indication for Aquipta in the EU, where it is now approved both for acute attacks and as a once-daily preventive treatment for adults experiencing The post AbbVie receives EC approval for Aquipta to treat migraine appeared first on Pharmaceutical Business review....

The application seeks approval of giredestrant as an adjuvant treatment for adults with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, stage I to III breast The post Roche's giredestrant secures FDA priority review for breast cancer appeared first on Pharmaceutical Business review....

The regulator granted the application priority review for this indication, assigning a Prescription Drug User Fee Act (PDUFA) date of 30 September 2026. Camzyos is currently approved for The post BMS secures FDA acceptance for Camzyos sNDA appeared first on Pharmaceutical Business review....

The value includes a $1.55bn upfront payment and as much as $1.1bn in regulatory and commercial milestone payments. The acquisition aligns with Servier's strategic goal in rare neurology, The post Servier to acquire Edgewise's muscular dystrophy business for $2.65bn appeared first on Pharmaceutical Business review....

The agreement covers Hanmi's candidate that uses its LAPSCOVERY long-acting platform technology. Sonefpeglutide combines Hanmi's proprietary technology and has previously achieved approval from the US Food and Drug The post Lilly and Hanmi sign $1.26bn licensing deal for sonefpeglutide appeared first on Pharmaceutical Business review....

This marks the first approved immunotherapy combination for this patient segment in the US. The approval relies on positive data from the POTOMAC Phase III trial, which was The post FDA approves AstraZeneca's Imfinzi-BCG combination for NMIBC therapy appeared first on Pharmaceutical Business review....

The agreement covers antibody-drug conjugates with new payloads and multi-specific antibodies featuring distinct immune-engaging mechanisms. The portfolio consists of eight drug candidates originating from Innovent Biologics and four The post Pfizer and Innovent Biologics sign $10.5bn cancer drug development deal appeared first on Pharmaceutical Business review....

If approved, venglustat would be the first treatment in the US to address the neurological symptoms of GD3, which currently have no targeted therapies. The decision is anticipated The post FDA grants priority review for Sanofi's venglustat NDA appeared first on Pharmaceutical Business review....

This move strengthens vaccine supply resilience in Colombia and creates a pathway for SK bioscience's expansion into Latin America. The Colombian Ministry of Health and Social Protection, National The post SK bioscience and VECOL partner on Colombia vaccine manufacturing initiative appeared first on Pharmaceutical Business review....

Elunetirom is an oral, once daily, brain-penetrant CNS thyroid hormone receptor (CNS-TR) agonist in development for bipolar depression and major depressive disorder (MDD). The therapy is intended as The post Autobahn's elunetirom receives FDA fast track designation to treat adjunctive bipolar appeared first on Pharmaceutical Business review....

The therapy uses patients' immune cells, developed into mature macrophages, which are then re-infused to break down scar tissue and promote the growth of healthy liver cells. In The post University of Edinburgh develops cell therapy for liver disease appeared first on Pharmaceutical Business review....

The recommendation covers the use of the therapy in combination with cetuximab and Folfox as a first-line treatment option for adult patients with BRAFV600E-mutant mCRC. This represents a The post Pierre Fabre's Braftovi gains CHMP positive opinion for mCRC appeared first on Pharmaceutical Business review....

The approval allows Datroway to be used as a first-line treatment for adults with unresectable or metastatic TNBC who cannot receive programmed cell death protein 1 (PD-1) or The post AstraZeneca, Daiichi Sankyo's Datroway receives FDA approval for TNBC appeared first on Pharmaceutical Business review....

The collaboration aims to accelerate hit identification for these companies through a fee-for-success approach. It will combine OpenBench's AI-based discovery platform with Concept Life Sciences' expertise in medicinal The post Concept Life Sciences and OpenBench partner on drug discovery services appeared first on Pharmaceutical Business review....

First announced last month, the move aims to advance Gilead's oncology portfolio. Under the agreement, the company acquired all outstanding equity of Tubulis for $3.15bn upfront on a The post Gilead Sciences acquires Tubulis for $5bn appeared first on Pharmaceutical Business review....

The site is anticipated to expand the company's production capacity for iPSC-based research products and services to four times its previous levels. Fujifilm Cellular Dynamics plans to use The post FUJIFILM opens new iPSC facility in Madison, US appeared first on Pharmaceutical Business review....

The initiative will embed agentic capabilities throughout BMS' research, clinical, manufacturing, commercial, and corporate operations. It aims to shift from basic conversational AI towards advanced agentic tools within The post BMS and Anthropic collaborate for Claude implementation appeared first on Pharmaceutical Business review....

The move aims to allow pharmaceutical and biotechnology researchers to use AI more effectively by leveraging enhanced bioinformatics tools and curated knowledge bases. The integration also aims to The post QIAGEN and NVIDIA partner on AI drug discovery appeared first on Pharmaceutical Business review....